Add To Watchlist
Share URL
About The Company
Description
Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia.
Read More
Overview
Value
16
Growth
20
Health
54
Management
28
Analyst Opinion
74
Total
38
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Liked by analysts
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Poor earnings and cashflow growth
- Price-to-earnings ratio of 143.8 is higher than the market average (19.6x)
- High preportion of income is paid as dividend
Market Peers
0455.HK
Key Figures
PE Ratio (TTM)
143.84
Margin Of Safety (DCF)
8.03%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Buy
Share Buybacks
N/A
Dividend Yeild (TTM)
0.47%
Valuation
Value Score
16
- ✔ Estimated intrinsic-value of 226.86 undefined HKD is higher than current price ( 210.00 undefined HKD)
- ✘ Price-to-earnings ratio of 143.8 is higher than the market average (19.6x)
- ✘ Free-cashflow-yeild of -27.08% is worse than the market average (4.7%)
- ✘ Margin-of-safety of 8.03% is worse than the market average (17.95%)
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 0.2 HKD ✘
Current Price: 0.2 HKD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
143.84x
Free Cashflow Yeild
-27.08%
PE/Earnings Growth
N/A
Price/Book
0.67x
Growth
Growth Score
20
- ✔ Earnings growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ Revenue growth has slowed this year
- ✘ 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
N/A
Earnings Growth
N/A
Cashflow Growth
N/A
Health
Health Score
54
Altman Z Score
1.63
Piostroski Score
4.00
Debt/Equity
0.11x
Current Assets/Liabilities
3.77x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.15x
Dividend
Secure Dividend Score
52
- ✔ Dividend is likely safe
- ✔ Dividends have shown growth over the last 5 years
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Dividend yeild of 0.47% is less than the market average (1.85%)
- ✘ Long term dividend payout ratio of 142.78% is high and may limit growth
- ✘ Payout ratio (TTM) of 67.92% is higher than the average (40%)
Dividend Yeild
0.47%
Dividend Growth
N/A
Payout Ratio (Earnings)
67.92%
Payout Ratio (Cashflow)
-1.75%
Management
Management Score
28
Average Buybacks/Dilution
N/A
Recent Buybacks/Dilution
-0.00%
5 Year Price Volitility
19.91%
Return On Assets
0.08%
Return On Capital Employed
1.09%
Return On Equity
0.10%
Return On Free Cashflow
-2.57%
Return On Investments
20.17%
Analysts
Analyst Opinion
74
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Tianda Pharmaceuticals Limited
Currency
HKD
Beta
0.229803
Vol Avg
808037
Ceo
Mr. Wen Quan Fang
Cik
Cusip
Exchange
HKSE
Full Time Employees
699
Industry
Drug Manufacturers—Specialty & Generic
Sector
Healthcare
Ipo Date
2000-01-03
Address
CITIC Tower
City
Central
State
Country
HK
Zip
Phone
852 2545 3313
All financial data provided by FMP